Noel Garber’s Post

View profile for Noel Garber, graphic

PhD Candidate Researcher at the University of Toronto

Signed! It is essential in modern regulatory affairs that the culture of development moves towards a more proactionary approach that weighs risk of trying an untested new therapy against the risk of doing nothing. For patients who have severe incurable disease that will inevitably be life-ending or severely life-altering, it can be worth trying something radically new, even if the risk is high. The worst that can happen in such cases is often no worse than what would naturally transpire if nothing was done.

To view or add a comment, sign in

Explore topics